Document Detail


Recombinant activated factor VII as treatment for uncontrolled mucosal haemorrhage.
MedLine Citation:
PMID:  22693200     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We report the use of a haemostatic drug (recombinant activated factor VII (rFVIIa)) in a patient who presented a slow but constant bleed in oesophageal mucosa (which required frequent red blood cell transfusion) due to ingestion of caustic products. The administration of rFVIIa ceased bleeding and allowed mucosal cicatrisation and patient haemodynamic stabilisation and clinical recovery.
Authors:
J Gracia; I Prieto
Publication Detail:
Type:  Case Reports; Journal Article     Date:  2011-06-29
Journal Detail:
Title:  BMJ case reports     Volume:  2011     ISSN:  1757-790X     ISO Abbreviation:  BMJ Case Rep     Publication Date:  2011  
Date Detail:
Created Date:  2012-06-13     Completed Date:  2013-04-29     Revised Date:  2013-07-12    
Medline Journal Info:
Nlm Unique ID:  101526291     Medline TA:  BMJ Case Rep     Country:  England    
Other Details:
Languages:  eng     Pagination:  -     Citation Subset:  IM    
Affiliation:
Department of ICU, Ramon y Cajal Hospital, Madrid, Spain. jan.grazia@gmail.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Esophageal Diseases / drug therapy*
Factor VIIa / therapeutic use*
Hemorrhage / drug therapy*
Humans
Male
Mucous Membrane
Recombinant Proteins / therapeutic use
Chemical
Reg. No./Substance:
0/Recombinant Proteins; 0/recombinant FVIIa; EC 3.4.21.21/Factor VIIa
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Atypical rabies with MRI findings: clue to the diagnosis.
Next Document:  Giant melanoma of the scalp--discussion of a rare clinical presentation.